60 Degrees Pharmaceuticals, Inc. (SXTPW)

Market Cap	5.17M
Revenue (ttm)	984,494
Net Income (ttm)	-8.31M
Shares Out	4.10M
EPS (ttm)	-7.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0110 - 0.1560
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2025

About SXTPW

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: SXTPW
• Website: https://www.60degreespharma.com